Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  




2 External links  













Idursulfase






●تۆرکجه
 ●فارسی
 ●Français
 ●Italiano
 ●Nederlands
 ●日本語
 ●ଓଡ଼ିଆ
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Svenska
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Idursulfase
Clinical data
AHFS/Drugs.comMonograph
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
 ☒NcheckY (what is this?)  (verify)

Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II).[2] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[3][4][5]

References

[edit]
  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  • ^ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
  • ^ "Drug approved to treat rare but potentially deadly disease". Archived from the original on 2011-02-24. Retrieved 2011-04-29.
  • ^ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
  • ^ [1], Barbara Kollmeyer, Marketwatch, Fed. 3, 2016
    • [edit]


    Stub icon

    This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Idursulfase&oldid=1218286543"
    Categories: 
    ●Orphan drugs
     ●Drugs developed by Takeda Pharmaceutical Company
     ●Gastrointestinal system drug stubs
     Hidden categories: 
    ●Drugs with non-standard legal status
     ●Chemicals that do not have a ChemSpider ID assigned
     ●Articles with changed EBI identifier
     ●Infobox drug articles without a structure image
     ●Articles without InChI source
     ●Drugs with no legal status
     ●Drug has EMA link
     ●Drugboxes which contain changes to verified fields
     ●All stub articles
      


    ●This page was last edited on 10 April 2024, at 20:30 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki